|
1
|
Sunitinib in patients with metastatic renal cell carcinoma.
|
JAMA
|
2006
|
11.33
|
|
2
|
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2005
|
9.05
|
|
3
|
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
|
J Clin Oncol
|
2009
|
8.16
|
|
4
|
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
|
J Clin Oncol
|
2008
|
5.27
|
|
5
|
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
|
Clin Cancer Res
|
2009
|
5.10
|
|
6
|
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
|
Lancet Oncol
|
2007
|
4.40
|
|
7
|
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
|
J Clin Oncol
|
2004
|
4.25
|
|
8
|
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
|
N Engl J Med
|
2015
|
4.24
|
|
9
|
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
3.79
|
|
10
|
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
|
Lancet Oncol
|
2013
|
3.19
|
|
11
|
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
|
J Transl Med
|
2007
|
2.90
|
|
12
|
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
|
Lancet Oncol
|
2012
|
2.84
|
|
13
|
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
|
J Urol
|
2010
|
2.73
|
|
14
|
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
|
Clin Cancer Res
|
2007
|
2.71
|
|
15
|
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma.
|
Cancer Res
|
2010
|
2.61
|
|
16
|
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
|
J Clin Oncol
|
2012
|
2.61
|
|
17
|
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
|
AJR Am J Roentgenol
|
2010
|
2.44
|
|
18
|
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
|
Cancer Res
|
2009
|
2.32
|
|
19
|
Surgical resection of renal cell carcinoma after targeted therapy.
|
J Urol
|
2009
|
2.29
|
|
20
|
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
|
Cancer
|
2007
|
2.25
|
|
21
|
Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association.
|
Am J Surg Pathol
|
2009
|
2.10
|
|
22
|
Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
|
J Urol
|
2008
|
2.03
|
|
23
|
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
|
J Clin Oncol
|
2004
|
2.02
|
|
24
|
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
|
J Clin Oncol
|
2008
|
2.00
|
|
25
|
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
|
J Urol
|
2008
|
1.87
|
|
26
|
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
|
Urology
|
2010
|
1.68
|
|
27
|
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
|
J Urol
|
2007
|
1.66
|
|
28
|
Recent progress in the management of advanced renal cell carcinoma.
|
CA Cancer J Clin
|
2007
|
1.62
|
|
29
|
State of the science: an update on renal cell carcinoma.
|
Mol Cancer Res
|
2012
|
1.58
|
|
30
|
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
|
Cancer
|
2011
|
1.56
|
|
31
|
Sunitinib rechallenge in metastatic renal cell carcinoma patients.
|
Cancer
|
2010
|
1.52
|
|
32
|
Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
|
Cancer
|
2011
|
1.52
|
|
33
|
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.
|
Cancer
|
2010
|
1.52
|
|
34
|
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.
|
Int J Cancer
|
2011
|
1.39
|
|
35
|
A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.
|
Cancer
|
2009
|
1.30
|
|
36
|
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.
|
J Clin Oncol
|
2010
|
1.23
|
|
37
|
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
|
J Urol
|
2010
|
1.22
|
|
38
|
Prolonged complete responses and near-complete responses to sunitinib in metastatic renal cell carcinoma.
|
Clin Genitourin Cancer
|
2007
|
1.19
|
|
39
|
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
|
Cancer
|
2013
|
1.12
|
|
40
|
Novel agents in renal carcinoma: a reality check.
|
Ther Adv Med Oncol
|
2012
|
1.11
|
|
41
|
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
|
Semin Oncol
|
2009
|
1.10
|
|
42
|
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
|
Clin Cancer Res
|
2007
|
1.07
|
|
43
|
The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
|
Semin Oncol
|
2006
|
1.05
|
|
44
|
Von Hippel Lindau syndrome.
|
Adv Exp Med Biol
|
2010
|
1.04
|
|
45
|
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference.
|
Cancer
|
2009
|
1.04
|
|
46
|
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
|
Cancer
|
2010
|
1.02
|
|
47
|
Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
|
Cancer
|
2006
|
1.02
|
|
48
|
GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells.
|
Cancer Res
|
2009
|
1.00
|
|
49
|
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
|
Eur Urol
|
2011
|
1.00
|
|
50
|
Molecularly targeted therapy in renal cell carcinoma.
|
Expert Rev Anticancer Ther
|
2005
|
1.00
|
|
51
|
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
|
Cancer
|
2002
|
0.98
|
|
52
|
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
|
Clin Genitourin Cancer
|
2007
|
0.96
|
|
53
|
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
|
Target Oncol
|
2013
|
0.95
|
|
54
|
Targeted molecular therapy for renal cell carcinoma.
|
Urology
|
2007
|
0.95
|
|
55
|
Axitinib for renal cell carcinoma.
|
Expert Opin Investig Drugs
|
2008
|
0.94
|
|
56
|
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib.
|
Cancer
|
2010
|
0.92
|
|
57
|
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
|
BJU Int
|
2010
|
0.92
|
|
58
|
Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
|
Clin Prostate Cancer
|
2005
|
0.92
|
|
59
|
A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.
|
BJU Int
|
2006
|
0.92
|
|
60
|
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
|
Urol Oncol
|
2011
|
0.91
|
|
61
|
Current treatment considerations in metastatic renal cell carcinoma.
|
Curr Treat Options Oncol
|
2012
|
0.91
|
|
62
|
The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation.
|
Clin Genitourin Cancer
|
2007
|
0.89
|
|
63
|
Immunotherapy for metastatic renal cell carcinoma.
|
BJU Int
|
2007
|
0.88
|
|
64
|
Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.
|
Front Oncol
|
2012
|
0.88
|
|
65
|
Signal integration and gene induction by a functionally distinct STAT3 phosphoform.
|
Mol Cell Biol
|
2014
|
0.86
|
|
66
|
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
|
Cancer
|
2011
|
0.86
|
|
67
|
Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.
|
Cancer
|
2011
|
0.86
|
|
68
|
Prostate cancer immunology: biology, therapeutics, and challenges.
|
J Clin Oncol
|
2005
|
0.85
|
|
69
|
Determining the optimal dose and schedule of sunitinib: some answers, more questions.
|
Cancer
|
2011
|
0.83
|
|
70
|
Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.
|
J Clin Immunol
|
2011
|
0.83
|
|
71
|
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
|
Clin Genitourin Cancer
|
2008
|
0.83
|
|
72
|
Renal cell carcinoma.
|
Curr Opin Oncol
|
2007
|
0.83
|
|
73
|
Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.
|
Immunol Invest
|
2012
|
0.83
|
|
74
|
Quantifying hypertension in patients with cancer treated with sorafenib.
|
Lancet Oncol
|
2008
|
0.82
|
|
75
|
Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma.
|
Clin Genitourin Cancer
|
2006
|
0.80
|
|
76
|
Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
|
BJU Int
|
2011
|
0.80
|
|
77
|
Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.
|
BJU Int
|
2010
|
0.79
|
|
78
|
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
|
Clin Genitourin Cancer
|
2013
|
0.79
|
|
79
|
The ineligible patient: how to treat patients not included in clinical studies.
|
World J Urol
|
2013
|
0.78
|
|
80
|
The role of targeted therapy in metastatic renal cell carcinoma.
|
ScientificWorldJournal
|
2007
|
0.78
|
|
81
|
Renal cell carcinoma.
|
Curr Opin Oncol
|
2005
|
0.78
|
|
82
|
Targeted therapy in renal cell carcinoma.
|
Curr Opin Urol
|
2008
|
0.78
|
|
83
|
Integration of surgery and systemic therapy in the management of metastatic renal cancer.
|
Curr Urol Rep
|
2009
|
0.77
|
|
84
|
Emerging drugs for renal cell carcinoma.
|
Expert Opin Emerg Drugs
|
2010
|
0.77
|
|
85
|
Update on the use of mTOR inhibitors in renal cell carcinoma.
|
Clin Adv Hematol Oncol
|
2008
|
0.77
|
|
86
|
Editorial comment.
|
J Urol
|
2009
|
0.77
|
|
87
|
Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma.
|
Pharmacogenet Genomics
|
2017
|
0.77
|
|
88
|
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
Prostate
|
2009
|
0.76
|
|
89
|
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.
|
Invest New Drugs
|
2010
|
0.76
|
|
90
|
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
|
Clin Genitourin Cancer
|
2006
|
0.76
|
|
91
|
Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma.
|
J Endourol
|
2006
|
0.76
|
|
92
|
Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities.
|
Expert Rev Anticancer Ther
|
2008
|
0.76
|
|
93
|
Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.
|
Clin Pharmacokinet
|
2015
|
0.76
|
|
94
|
Editorial comment.
|
Urology
|
2010
|
0.75
|
|
95
|
Tumor Necrosis Adds Prognostically Significant Information to Grade in Clear Cell Renal Cell Carcinoma: A Study of 842 Consecutive Cases From a Single Institution.
|
Am J Surg Pathol
|
2016
|
0.75
|
|
96
|
Clinical trials in patients with biochemically relapsed prostate cancer.
|
BJU Int
|
2006
|
0.75
|
|
97
|
Therapeutic considerations in patients with metastatic renal cell carcinoma previously treated with antiangiogenic therapies.
|
Clin Genitourin Cancer
|
2006
|
0.75
|